curasan AG

euro adhoc: curasan AG
Curasan extends dental product range for US distribution
FDA grants 510(k) approval for Cerasorb® M Dental and Cerasorb® Perio

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


curasan AG - specialists in regenerative medicine - today received 510(k) approval by the FDA for Cerasorb® M Dental and Cerasorb® Perio.

Cerasorb® is a synthetic bone regeneration material that is fully resorbed by the body and replaced with autogenous bone. Cerasorb® M Dental is a second-generation product, featuring even faster resorption and bone replacement. It is used in regions exposed to lower loads and complements the classic Cerasorb®.

In addition, the company has developed a product by the name of Cerasorb® Perio, which is designed specifically for bone defects caused by periodontitis. Thus, curasan has taken a major step forward in terms of developing indication-specific Cerasorb® products.

"In autumn 2004, we introduced our own sales organisation for the US dental market. Cerasorb® M Dental and Cerasorb® Perio underline our ambitions as a leader within the field of state-of-the-art bone regeneration. Our target group will see the extension of our Cerasorb® portfolio as evidence of our commitment to the marketplace and will support our sales activities in this area," said curasan’s CEO H.D. Rössler.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. curasan AG's main goal is to occupy a leading position as a global specialist in Regenerative Medicine. For further information, please visit curasan’s corporate website at:

@@start.t2@@end of announcement                                                 euro adhoc 27.07.2005 16:32:26

ots Originaltext: curasan AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 465, eMail:

Branche: Biotechnology
ISIN:      DE0005494538
WKN:        549453
Börsen:    Frankfurter Wertpapierbörse
                Berliner Wertpapierbörse
                Hamburger Wertpapierbörse
                Baden-Württembergische Wertpapierbörse
                Börse Düsseldorf
                Niedersächsische Börse zu Hannover
                Bayerische Börse
                Bremer Wertpapierbörse (BWB)

Weitere Meldungen: curasan AG

Das könnte Sie auch interessieren: